REAch2 said reserves and GAG pooling would allow 'strategic' decisions and 'solidarity', but centralisation and a £2.5m restructure could prove controversial
CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease is a. | March 25, 2022